The German pharma and technology company said in a statement that earnings before interest, taxes, depreciation and ...

a jump of 11.8% and ahead of an average analyst estimate of 1.55 billion euros in a consensus posted on the company’s website ...

Notably, the study also showed that treatment with pimicotinib provided statistically significant and clinically meaningful improvements in secondary endpoints associated with important patient ...

Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) Statistically significant and clinically ...

The collaboration with Merck KGaA, Darmstadt, Germany focuses on discovering ... A live webcast of the presentation will be ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

DELRAY BEACH, Fla., Nov. 11, 2024 /PRNewswire/ -- The global synthetic biology market is anticipated to reach USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a significant CAGR of 20.6% ...

The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...

- European equities are up, yields flat and seeing a firmer US dollar as sentiment unchanged from yesterday, with higher ...